Hospital Finance Watch: Linkou Chang Gung Memorial Hospital topped Taiwan’s 240-hospital NHIA profit rankings for the 9th straight year in 2024, posting NT$3.726 billion, with about 90% of hospitals profitable overall. AI Drugmaking in Taiwan: Insilico Medicine and Bora Pharmaceuticals announced a multi-target AI alliance that could top US$2.5 billion, aiming to link AI-driven discovery with automation for development, manufacturing, quality, and commercialization. Food Safety Policy: Taiwan’s health minister defended raising the apple pesticide fenpropathrin residue limit to 3 ppm, saying it follows expert review and aligns with major markets, while critics question whether the change weakens long-standing safety safeguards. Aging & Care Access: Hearing-aid demand is rising as Taiwan ages, but stigma, price (often around US$2,000 per ear), and low awareness still delay treatment. Smart Hospitals: With staffing pressure growing, hospitals are turning to automated air-quality systems designed to reduce shared-air infection risk and cut maintenance, including less frequent filter replacement. Public Health Tech Research: An NTUH study suggests stool blood levels may help tailor colonoscopy follow-up, pointing to more personalized screening pathways. Drug Trial Updates: Kelun-Biotech reported Phase III progress for sacituzumab tirumotecan plus pembrolizumab in first-line PD-L1-negative non-squamous NSCLC, meeting its primary endpoint.